Loading
A phase 1/2 trial of pembrolizumab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Amsterdam UMC, location VUmc, now recruiting.
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) is a phase 1/2, interventional study registered as NCT06384560 by Amsterdam UMC, location VUmc, with a registry enrolment figure of 66 participants, started 2024-09-23 and due to reach its primary completion in 2028-03. Interventions recorded: Pembrolizumab; Folfirinox; SABR. Conditions listed: Localized Pancreatic Adenocarcinoma; Borderline Resectable Pancreatic Adenocarcinoma; Resectable Pancreatic Adenocarcinoma. Primary outcome: 1-year progression-free survival rate. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed adenocarcinoma of the pancreas (WHO VI or VII)". Sites: Netherlands. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Borderline resectable pancreatic ductal adenocarcinoma, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/